Armada Acquisition III agrees to combine with Brains Bioceutical

• Armada Acquisition III agreed to combine with Brains Bioceutical at an implied pre-money equity valuation of approximately $750 million.
• Existing Brains shareholders are expected to roll 100% of their equity into the combined company.
• The combined company is expected to operate as Brains Therapeutics, with common shares trading on Nasdaq under the ticker BAPI.
• Closing is expected in the second quarter of 2027, subject to shareholder approvals and other closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armada Acquisition Corp. III published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105333132) on November 05, 2026, and is solely responsible for the information contained therein.